Journal article
Immune response to COVID-19 vaccination is attenuated by poor disease control and antimyeloma therapy with vaccine driven divergent T cell response
- Abstract:
- Myeloma patients frequently respond poorly to bacterial and viral vaccination. A few studies have reported poor humoral immune responses in myeloma patients to COVID-19 vaccination. Using a prospective study of myeloma patients in the UK Rudy study cohort, we assessed humoral and interferon gamma release assay (IGRA) cellular immune responses to COVID-19 vaccination post second COVID-19 vaccine administration. We report data from 214 adults with myeloma (n = 204) or smouldering myeloma (n = 10) who provided blood samples at least three weeks after second vaccine dose. Positive Anti-spike antibody levels (> 50 iu/ml) were detected in 189/203 (92.7%), positive IGRA responses were seen in 97/158 (61.4%) myeloma patients. Only 10/158 (6.3%) patients were identified to have both a negative IGRA and negative anti-spike protein antibody response. In all, 95/158 (60.1%) patients produced positive results for both anti-spike protein serology and IGRA. After adjusting for disease severity and myeloma therapy, poor humoral immune response was predicted by male gender. Predictors of poor IGRA included anti-CD38/anti-BCMA (B-cell maturation antigen) therapy and Pfizer-BioNTech vaccination. Further work is required to understand the clinical significance of divergent cellular response to vaccination.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, 1.3MB, Terms of use)
-
- Publisher copy:
- 10.1111/bjh.18066
Authors
- Publisher:
- Wiley
- Journal:
- British Journal of Haematology More from this journal
- Volume:
- 197
- Issue:
- 3
- Pages:
- 293-301
- Publication date:
- 2022-02-17
- Acceptance date:
- 2022-01-15
- DOI:
- EISSN:
-
1365-2141
- ISSN:
-
0007-1048
- Pmid:
-
35064676
- Language:
-
English
- Keywords:
- Pubs id:
-
1235879
- Local pid:
-
pubs:1235879
- Deposit date:
-
2022-05-22
Terms of use
- Copyright holder:
- Ramasamy et al.
- Copyright date:
- 2022
- Rights statement:
- © 2022 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record